enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$2.41+0.13 (+5.70%)
Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%
enGene Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
enGene Therapeutics's ebitda for the twelve months ending Jul 31, 2026 was -$135.96M. For fiscal 2025 it was -$122.67M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$122.67M | – |
| FY2024 | Oct 31, 2024 | -$62.00M | – |
| FY2023 | Oct 31, 2023 | -$25.86M | – |
| FY2022 | Oct 31, 2022 | -$19.23M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$33.91M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$31.77M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$31.00M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$39.28M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$29.85M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$27.02M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$26.51M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$17.36M | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$16.66M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$17.21M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$10.69M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$10.37M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$6.21M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$4.70M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$4.59M | – |
See a number that looks wrong?